Rodman & Renshaw Initiates Coverage On Eledon Pharmaceuticals with Buy Rating, Announces Price Target of $12

Eledon Pharmaceuticals To Present Phase 2 BESTOW Trial At American Society Of Nephrology Kidney Week 2026 Annual Meeting

Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

Eledon Pharmaceuticals announced updated Phase 2 BESTOW extension study results showing tegoprubart-treated kidney transplant patients maintained significantly higher kidney function (71 vs. 58 mL/min/1.73 m² eGFR at 24 months) compared to tacrolimus, with zero rejections beyond six months versus seven in the tacrolimus arm. The FDA granted Fast Track designation to tegoprubart for kidney transplant rejection prevention, and the company plans to initiate the Phase 3 LEGACY trial in Q4 2026.

Eledon Presents Updated Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation At International Congress Of The Transplantation Society

Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus (71 vs. 58

Eledon Pharmaceuticals Says FDA Grants Fast Track Designation To Tegoprubart For Prevention Of Rejection In Kidney Transplantation; Expects To Initiate Phase 3 LEGACY Study In Q4 2026

Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus (71 vs. 58